Pharma Solutions

Supported by science

Omega-3 fatty acids EPA and DHA are investigated in clinical science for wide range of health conditions. Currently major therapeutic application of EPA and DHA is in CVD and refers to lowering plasma triglyceride levels.  Backed by extensive scientific evidence, EPA and DHA provide vital support to heart health in pharmaceutical applications, lowering plasma triglycerides levels, decreasing resting heart rate, blood pressure and inflammation, and improving vascular function.

Clinical trials referring to DHA and EPA cover such conditions as rheumatoid arthritis, osteoporosis, stroke, traumatic brain injury, cognitive decline, Alzheimer’s disease, depression, attention deficit/hyperactivity disorder, macular degeneration, asthma, inflammatory bowel disease, colon/breast/prostate cancer, skin disorders, sarcopenia, post-surgical recovery and others.

Contact us to find out more about our broad spectrum of EPA and DHA ingredients. 

March 19, 2018
Download our 2018 Pharmaceutical Solutions Brochure READ MORE
March 1, 2018
Meet with DSM at DCAT Week READ MORE
February 26, 2018
Take it to Heart: Exploring the Role of High-Dose B-Vitamin Therapy in CVD Risk Reduction READ MORE
February 2, 2018
Long-Chain n-3 Fatty Acids and Cancer Risk: What’s the Prognosis? READ MORE
December 1, 2017
Understanding Drug Nutrient Interactions READ MORE
November 14, 2017
DSM speaks at Nicholas Hall OTC Conference READ MORE